Kura Oncology Inc [KURA] stock is trading at $11.04, down -1.16%. An important factor to consider is whether the stock is rising or falling in short-term value. The KURA shares have gain 9.74% over the last week, with a monthly amount drifted -34.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $27. Previously, Stifel downgraded its rating to Hold on October 14, 2024, and dropped its price target to $19. On December 22, 2023, Mizuho initiated with a Buy rating and assigned a price target of $26 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $31 on August 11, 2023. Scotiabank initiated its recommendation with a Sector Perform and recommended $10.50 as its price target on July 27, 2023. BTIG Research started tracking with a Buy rating for this stock on May 17, 2023, and assigned it a price target of $31. In a note dated January 31, 2023, Stifel initiated an Buy rating and provided a target price of $25 on this stock.
Kura Oncology Inc [KURA] stock has fluctuated between $9.06 and $24.17 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $11.04 at the most recent close of the market. An investor can expect a potential return of 117.39% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.49% with Operating Profit Margin at -171.26%, Pretax Profit Margin comes in at -155.55%, and Net Profit Margin reading is -155.55%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.44 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.86 points at the first support level, and at 10.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.23, and for the 2nd resistance point, it is at 11.43.
Ratios To Look Out For
For context, Kura Oncology Inc’s Current Ratio is 11.47. On the other hand, the Quick Ratio is 11.47, and the Cash Ratio is 1.23.
Transactions by insiders
Recent insider trading involved FORD KATHLEEN, Chief Operating Officer, that happened on Nov 18 ’24 when 526.0 shares were sold. Officer, FORD KATHLEEN completed a deal on Nov 18 ’24 to buy 526.0 shares. Meanwhile, Chief Legal Officer Bair Teresa Brophy sold 2615.0 shares on May 20 ’24.
